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A B S T R A C T
Nucleic acid ampliﬁcation tests such as Xpert MTB/RIF (Xpert) have the potential to revolutionize tuberculosis
(TB) diagnostics and improve case ﬁnding in resource-poor settings. However, since its introduction over a
decade ago in Uganda, there remain signiﬁcant gaps along the cascade of care for patients undergoing TB
diagnostic evaluation at peripheral health centers. We utilized a systematic, implementation science-based ap-
proach to identify key reasons at multiple levels for attrition along the TB diagnostic evaluation cascade of care.
Provider- and health system-level barriers ﬁt into four key thematic areas: human resources, material resources,
service implementation, and service coordination. Patient-level barriers included the considerable costs and time
required to complete health center visits. We developed a theory-informed strategy using the PRECEDE fra-
mework to target key barriers by streamlining TB diagnostic evaluation and facilitating continuous quality
improvement. The resulting SIMPLE TB strategy involve four key components: 1) Single-sample LED ﬂuores-
cence microscopy; 2) Daily sputum transport to Xpert testing sites; 3) Text message communication of Xpert
results to health centers and patients; and 4) Performance feedback to health centers using a quality improve-
ment framework. This combination of interventions was feasible to implement and signiﬁcantly improved the
provision of high-quality care for patients undergoing TB diagnostic evaluation. We conclude that achieving high
coverage of Xpert testing services is not enough. Xpert scale-up should be accompanied by health system co-
interventions to facilitate eﬀective implementation and ensure that high quality care is delivered to patients.
1. Introduction
The World Health Organization (WHO) estimates that at least one-
third of tuberculosis (TB) patients worldwide are not being diagnosed
or treated - the so called “Missing 3 Million” [1]. Better diagnostics are
critical to improving case ﬁnding and ultimately patient and public
health outcomes. Smear microscopy has been the standard of care for
over 100 years but has poor sensitivity, missing at least half of all TB
cases [2]. Smear microscopy also requires patients to make multiple
visits to health centers, resulting in high rates of loss to follow up [3,4].
To improve case detection, there has been considerable donor and
country investment in novel diagnostics. However, there has been re-
latively little attention paid to the quality of care provided alongside
new diagnostics to patients undergoing TB diagnostic evaluation.
In 2010, Xpert MTB/RIF (Xpert) became the ﬁrst nucleic acid am-
pliﬁcation test endorsed by the WHO [5], with subsequent guidelines in
2013 endorsing Xpert as the ﬁrst-line TB test for all patients [6]. Xpert
is a semi-automated PCR-based test that is more sensitive than micro-
scopy (85% vs 50–60%) [7] and provides results within two hours,
including whether or not rifampin resistance is present. Since its
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endorsement by the WHO, Xpert testing capacity has been scaled-up
rapidly in high burden countries [8]. By the end of 2016, a total of 6659
GeneXpert instruments (comprising 29,865 modules) and more than 23
million cartridges had been procured in the public sector in 130 of the
145 countries eligible for concessional pricing [9]. The number of
modules and cartridges has continued to increase exponentially in the
past few years.
Uganda has been a leader in the scale-up of Xpert on a population
basis [8,10,11]. Similar to many other high burden countries, the
Uganda National Tuberculosis and Leprosy Program (NTLP) and Na-
tional Tuberculosis Reference Laboratory (NTRL) established a hub-
and-spoke model for nationwide roll-out of Xpert in 2012 [12]. Testing
sites (i.e., hubs), now present in most districts of the country, are linked
with 3–5 peripheral microscopy units (i.e., spokes). Sputum samples
collected at the peripheral microscopy units are transported to the
testing hubs and results are returned to the microscopy centers after
testing is completed. The NTRL has also installed GxAlert (SystemOne,
USA) software at testing hubs to enable central monitoring of test re-
sults and device performance.
No formal impact studies of this massive scale-up of Xpert testing
have been carried out. Review of national case reporting data indicates
a nearly four-fold increase in conﬁrmed MDR TB patients from 2009 to
2017, small increases in TB case notiﬁcation from 40 to 42,000 cases
before 2010 to 57,756 cases in 2017, and an increase in the proportion
of bacteriologically-conﬁrmed cases from 60% to 65% to 87% in the
same period [13]. However, while some of these increases are poten-
tially attributable to Xpert scale-up, there remain unresolved questions
critical to understanding the eﬀectiveness of Xpert scale-up and to
identifying opportunities to further improve case ﬁnding. These in-
clude: How rapidly and eﬃciently are Xpert referral networks func-
tioning from both the health system and patient perspectives?; What is
the variability in quality of TB diagnostic care within Xpert referral
networks?; and What policy changes and co-interventions could further
enhance Xpert implementation?
Over the past 3–4 years, we have tried to address some of these
questions in a collaborative partnership with the Uganda NTLP and
NTRL. Our objectives have been to:
1) Quantify gaps in the process of TB diagnostic evaluation at periph-
eral health centers linked to Xpert testing sites.
2) Identify modiﬁable barriers to high quality TB diagnostic evalua-
tion; and
3) Develop and test theory-driven interventions to improve the quality
of TB diagnostic evaluation.
All summarized studies underwent review by Institutional Review
Boards (IRBs) at both the University of California, San Francisco (UCSF)
and Makere University, and participants were appropriately consented
except when IRBs granted an explicit waiver of informed consent.
2. Deﬁning the quality gap
To deﬁne the quality gap, we assessed adherence to national and
international guidelines [12,14,15]for evaluation of patients with pre-
sumed TB at 24 peripheral health centers (hubs) linked to 16 Xpert
MTB/RIF testing sites (spokes; Fig. 1) [16]. We included health centers
that: (1) used sputum smear microscopy as the primary method of TB
diagnosis; (2) participated in NTLP-sponsored external quality assur-
ance for sputum smear microscopy; and (3) referred sputum samples to
a district or regional health facility for Xpert testing. We excluded
health centers that (1) performed sputum smear microscopy on less
than 150 patients per year and (2) diagnosed less than 15 smear-posi-
tive TB cases per year using data from 2015. 24 health centers meeting
these criteria and located outside of, but within 150 km of the capital
region of Kampala were selected in consultation with the Uganda NTLP.
We prospectively extracted individual patient data from routine TB
registers on all adults evaluated for pulmonary TB at these health
centers. We excluded data on patients who (1) had sputum collected for
monitoring of response to anti-TB therapy; (2) had sputum collected as
part of active, community-based case ﬁnding (e.g., contact tracing,
community outreach campaign); (3) had a documented prior history of
TB treatment (e.g., reason for Xpert testing or TB treatment marked as
treatment failure, relapse, or treatment after loss to follow-up); (4) were
referred to a study health center for TB treatment after a diagnosis was
established elsewhere; (5) were started on treatment for presumptive
extra-pulmonary TB only; or (6) were less than 18 years old. Data from
TB registers were used to capture their outcomes at each step of the TB
diagnostic evaluation cascade of care, including whether they under-
went sputum-based TB testing, TB testing dates and results, and treat-
ment initiation dates. We used these data to assess quality indicators
derived from national and international guidelines for TB care
[12,14,15]: 1) the proportion of patients with presumed TB referred for
sputum-based TB testing; 2) the proportion completing TB testing if
referred (deﬁned based on national guidelines as a single valid Xpert
result or examination of at least two sputum smears (if HIV-negative);
and 3) the proportion rapidly (i.e., within 14 days) initiated on TB
treatment if smear- or Xpert-positive.
Over a 12-month period from January to December 2017, 6744
adults underwent evaluation for pulmonary TB at the 24 study sites
[16]. We found that 79% were referred for sputum-based TB testing,
56% completed TB testing if referred, and 75% were treated within 14
days if smear or Xpert results were positive. The gaps at each step in-
dicate that the cumulative probability of a patient with sputum smear-
or Xpert-positive TB being diagnosed and treated upon presenting to
these health centers was only a 43%. In addition, with respect to Xpert
utilization, only 20% of patients with presumed TB (33% of people
living with HIV infection (PLHIV) and 7% of people living without HIV
infection) were referred for Xpert testing, and only 53% of patients with
positive Xpert results were initiated on treatment within 14 days. The
low uptake of Xpert testing for PLHIV is particularly concerning as rates
of smear-negative disease are higher and thus continued reliance on
smear microscopy can lead to unacceptably high rates of false-negative
results [17].
Data from quality indicators at 24 peripheral health centers in
Uganda demonstrated that despite rapid scale-up of Xpert testing using
a hub-and-spoke model, the overall quality of TB diagnostic evaluation
remains poor and that there are considerable opportunities to enhance
Xpert implementation. In particular, few patients received Xpert testing
(including those recommended to have Xpert as a ﬁrst-line test) and
nearly half with positive Xpert results were not being rapidly linked to
treatment. In addition, we also showed that it is possible to use routine
data sources to monitor and improve the quality of TB services at the
facility-level, a capacity that is an important pre-requisite for estab-
lishing any mechanism for continuous quality improvement.
3. Understanding the quality gap
We conducted a series of mixed methods studies using the Theory of
Planned Behavior as our conceptual model. This is a well-known be-
havioral theory proposed by Ajzen in 1985 to understand factors that
aﬀect an individual's intention to carry out a certain behavior [18].
According to this theory, clinicians’ knowledge and attitudes, perceived
social pressure, and perceived behavior control will impact their in-
tention to follow TB diagnostic evaluation guidelines. In addition, we
hypothesized that certain patient- and health system-level factors might
make it easier or harder to take up or consistently adhere to guidelines
(Fig. 2). We collected data on these factors using qualitative and
quantitative approaches.
From interviews (N=22 staﬀ at 6 health centers) and ﬁeld ob-
servation of health center staﬀ (one 2–3 day ﬁeld visit at each of 6
health centers), we identiﬁed key barriers across four thematic areas:
human resources, material resources, service implementation, and
A. Cattamanchi, et al. J Clin Tuberc Other Mycobact Dis 18 (2020) 100136
2
Fig. 1. Location of study sites. The map shows the location of study sites, including 24 peripheral health centers with TB microscopy units (circles) and the17 Xpert
testing sites (triangles) to which they refer sputum samples.
Fig. 2. Conceptual model for understanding reasons for gaps in TB diagnostic evaluation. We used the Theory of Planned Behavior to identify factors asso-
ciated with provider's intention to follow guidelines for TB diagnostic evaluation. We also collected data on patient and health system factors that might inﬂuence
sustained guideline adherence.
ISTC International Standards of Tuberculosis Care [29].
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service coordination [19]. Human resource barriers to guideline ad-
herence included lack of knowledge about current guidelines; a lack of
skills (microscopy); belief that TB evaluation is not urgent; and low self-
eﬃcacy due to heavy workloads in the laboratory and low conﬁdence
that patients will return regardless of their eﬀorts. Providers at local
facilities also cited issues with the material resources required to con-
duct their work, including stock outs of sputum cups, reagents, and
medicines; limited space for assessing and counseling patients; and
poorly ventilated laboratory facilities. Barriers to service implementa-
tion included high staﬀ turnover, inconsistent and delayed specimen
transport to Xpert testing sites, and the inability to track and follow-up
with patients with positive TB test results. Finally, health center staﬀ
noted several examples of poor service coordination that contributed to
their inability to provide high quality care. These included a lack of
regular communication among health center staﬀ and insuﬃcient
oversight from NTLP supervisors.
Through surveys of patients (N=64) and community members
(N=114) [20], we learned that pathways for patients seeking care for
chronic cough were complex and costly. Most (>80%) patients made
repeated health facility visits (median 3 visits), and most visits (88%)
were to health facilities that did not provide TB diagnostic services. The
most common health facilities visited were pharmacies, community
health posts and private clinics, and many patients made repeated visits
to the same facility. The costs of seeking care for TB symptoms were
high, accounting for on average 29% of monthly household income.
Visiting a Level IV health center where TB microscopy and Xpert re-
ferral are possible alone accounted for 11% of monthly household in-
come and took upwards of 9 h to complete. The substantial time and
cost inherent in seeking care for TB symptoms impacts patient behavior
– 40% of patients surveyed indicated they were unlikely to complete
additional visits, even when recommended, to obtain additional testing
or receive results.
Last, we conducted additional interviews and observations at 23
peripheral health centers and the 15 sites to which they referred sputum
samples for Xpert testing. [21] The results identiﬁed barriers at each
step of the process for referring samples for Xpert testing. Challenges
with sputum collection for Xpert testing included a shortage of sputum
containers (8/23 health centers) and lack of refrigerators for sputum
storage prior to transport (10/23 health centers). The latter resulted in
health centers only collecting specimens for Xpert testing on days when
transport was expected to happen. Sputum transportation to Xpert
testing facilities (hubs) was irregular and varied in frequency from 1 to
3 times/week. Xpert testing at hubs was limited by non-functioning
modules (5/15 testing sites), lack of back-up electricity (2/15 testing
sites) and failure to implement daily device maintenance (7/15 testing
sites) resulting in unacceptably high (>5%) error/invalid rates (10/15
testing sites). Notiﬁcation of results to referring health centers was
often delayed, typically taking up to 2 weeks.
In consultation with multiple key local stakeholders involved in the
provision of TB care, including NTLP oﬃcials and clinicians involved in
front-line TB care, we prioritized and selected barriers to target for
intervention using the PRECEDE framework, a well-validated frame-
work for designing behavior change interventions [22]. The framework
classiﬁes barriers as predisposing, enabling, or reinforcing factors
(Table 1). Interventions that target barriers within all three of these
categories are more likely to result in successful behavior change [22].
The barriers selected to target for intervention included: 1) pre-dis-
posing factors: low self-eﬃcacy due to time and resource constraints,
and the belief that TB evaluation is not urgent; 2) enabling factors:
failure of patients to return after their initial health center visit (due to
time and costs), inconsistent and delayed transport to Xpert testing
sites, and inability to track and follow-up patients; and 3) reinforcing
factors: a lack of communication and coordination among staﬀ and
insuﬃcient oversight from NTLP supervisors (Table 1).
4. Improving the quality gap
We sought to design an intervention to improve the quality of TB
diagnostic services within the hub-and-spoke model for Xpert testing
that targeted the key barriers that we had identiﬁed through our for-
mative research. To do so, we reviewed the literature and consulted
with stakeholders (health workers, health center directors, district
health oﬃcers, NTLP oﬃcials) regarding the feasibility and accept-
ability of each of the potential intervention options. The resulting
“SIngle-saMPLE (SIMPLE) TB evaluation strategy included four key
components:
1) Single-sample LED ﬂuorescence microscopy was selected because of
its ability to provide a TB diagnosis and initiate treatment at the
initial visit for the majority of patients with TB. The patient barriers
targeted included the high-cost of clinic visits. The health-system
barriers targeted include the high laboratory workload and the
prevailing belief among clinicians that TB evaluation is not urgent.
The intervention involved on-demand preparation/examination of
two smears from a single sputum sample, an approach we have
previously shown is as accurate as examining smears from diﬀerent
samples [23].
2) Daily sputum transport to Xpert testing hubs was selected to facil-
itate same-day (or next-day) Xpert testing for all smear-negative
patients. The barriers targeted included the failure of patients to
return after their initial health center visit and inconsistent or de-
layed specimen transport to Xpert testing sites. This intervention
involved identifying a primary and alternate boda boda (motor-
cycle) rider for each peripheral health center, linking the riders to
laboratory staﬀ, and tracking sample pick-up and delivery using a
paper logbook.
3) Short Message Service (SMS)-based communication of Xpert results
to health centers and patients was selected to reduce delays in re-
porting results and improve linkage to treatment. The barriers tar-
geted included the failure of patients to return after their initial
health center visit and inability of health center staﬀ to track and
follow-up such patients. This intervention involved installing
GxAlert software (System One, Northampton, USA) and a USB
modem at all Xpert testing hubs, establishing an automated SMS
platform linked to a central GxAlert server at the Uganda National
TB Reference Laboratory and training staﬀ at Xpert testing hubs to
use GxAlert software.
4) Performance feedback was selected to facilitate continuous quality
improvement. The barriers targeted included lack of communication
and coordination between health center staﬀ and insuﬃcient over-
sight from NTLP supervisors. It involved providing health centers
with a monthly report card with quality indicators reﬂecting ad-
herence to each step of TB diagnostic evaluation and training health
center staﬀ to review and discuss report cards amongst themselves
at monthly staﬀ meetings using a Plan-Do-Study-Act (PDSA) fra-
mework [24,25].
We had previously shown that performance feedback was feasible as
an informal quality improvement (QI) strategy and led to a 15% (from
52% to 67%) increase in the proportion of patients receiving guideline-
adherent care at 6 peripheral health centers [26]. To assess the feasi-
bility and potential impact of the remaining three components, we
conducted a single-arm interventional study at 5 peripheral microscopy
units linked to an Xpert testing hub [27]. Using data from all adults
(N=1212) undergoing TB evaluation over a 14-month period from
February 2015 to April 2016, we showed that 99% were referred for
sputum-based TB testing, 99.6% completed testing if referred and 86%
of patients with conﬁrmed TB were treated rapidly (within 14 days).
The probability of a patient with sputum smear- or Xpert-positive TB
being diagnosed and treated was 85%, nearly double what was ob-
served under the routine hub-and-spoke model. With respect to Xpert
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utilization, 83% of smear-negative patients were referred for Xpert
testing within one day and 76% of Xpert-positive patients initiated
treatment within 14 days, both considerable improvements relative to
routine care. In addition, automated notiﬁcation of Xpert results
reached referring health centers 95% of the time and patients 49% of
the time [28]. These data demonstrate that the theory-informed
SIMPLE TB strategy is feasible and eﬀective at improving the quality of
TB diagnostic evaluation. However, there remain further opportunities
for improving linkage to care, particularly for patients with smear-ne-
gative but Xpert-positive TB.
5. Conclusion
To make progress towards elimination, donor and country funding
for scaling-up novel diagnostics is essential. However, there needs to be
greater investment focused on improving the quality of TB care that
accompanies funding to achieve maximal impact of novel diagnostics
such as Xpert. This investment should include speciﬁc funds for co-in-
terventions such as training, process re-design, performance feedback
and ancillary infrastructure (specimen transport, results notiﬁcation,
etc.) relevant to the local context and barriers to high-quality service
delivery. Proper implementation supports are essential for new diag-
nostics to fully realize their promising potential. Implementation sci-
ence-based approaches can facilitate a systematic assessment of key
barriers and enablers and guide selection of the most appropriate and
feasible implementation supports for a given context.
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